OPKO Health, Inc. (OPK) Key Metrics
OPK valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.14B
- Enterprise value
- $1.37B
- P/E (TTM)
- —
- Forward P/E
- 53.8
- PEG ratio
- 93.65
- Price / sales
- 1.9 10-yr median 1.6
- Price / book
- 1.1 10-yr median 0.9
- EV / EBITDA
- 24.9 10-yr median 28.2
- Dividend yield
- —
- Beta
- 1.50
OPK key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOPK valuation Price multiples at each fiscal year-end price.
OPK returns How much profit the business earns on the capital it uses.
OPK per-share figures Results divided by the shares outstanding at year-end.
OPK financial health Debt, liquidity and how easily interest is covered.
OPK efficiency & capital use Working capital cycle and where the cash goes.
OPK valuation history
OPK returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OPK debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OPK cash returned to shareholders
OPK price vs earnings per share
OPK key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $946.4M | $1.02B | $1.14B | $898.8M | $3.12B | $2.53B | $875.3M | $1.71B | $2.74B | $4.67B |
| Enterprise value | $1.01B | $1.09B | $1.37B | $1.05B | $3.24B | $2.75B | $1.08B | $1.82B | $2.81B | $4.59B |
| P/E ratio | — | — | — | — | — | 82.7 | — | — | — | — |
| Price / sales | 1.6 | 1.4 | 1.3 | 0.9 | 1.8 | 1.8 | 1.0 | 1.7 | 2.8 | 3.8 |
| Price / book | 0.7 | 0.7 | 0.8 | 0.6 | 1.8 | 1.5 | 0.5 | 1.0 | 1.5 | 2.2 |
| Price / free cash flow | — | — | — | — | 504.3 | 436.8 | — | — | — | 549.3 |
| Price / operating cash flow | — | — | — | — | 81.3 | 64.1 | — | — | — | 145.7 |
| EV / sales | 1.7 | 1.5 | 1.6 | 1.0 | 1.8 | 1.9 | 1.2 | 1.8 | 2.9 | 3.8 |
| EV / EBITDA | — | 8.1 | — | — | 38.7 | 17.6 | — | — | — | 638.7 |
| EV / free cash flow | — | — | — | — | 523.8 | 475.1 | — | — | — | 539.9 |
| Earnings yield | −23.8% | −5.2% | −16.6% | −36.5% | −1.0% | 1.2% | −36.0% | −9.0% | −11.1% | −1.0% |
| Free cash flow yield | −20.2% | −20.4% | −3.9% | −13.3% | 0.2% | 0.2% | −21.2% | −8.0% | −5.1% | 0.2% |
| Dividend yield | — | — | — | — | — | — | 0.0% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 5.0% | 8.8% | 0.0% | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $1.26 | $1.47 | $1.51 | $1.25 | $4.81 | $3.95 | $1.47 | $3.01 | $4.90 | $9.30 |
| Per share | ||||||||||
| Revenue per share | $0.81 | $1.03 | $1.15 | $1.40 | $2.74 | $2.24 | $1.51 | $1.75 | $1.73 | $2.43 |
| Earnings per share | −$0.30 | −$0.08 | −$0.25 | −$0.46 | −$0.05 | $0.05 | −$0.53 | −$0.27 | −$0.55 | −$0.10 |
| Operating cash flow per share | −$0.24 | −$0.26 | −$0.04 | −$0.13 | $0.06 | $0.06 | −$0.29 | −$0.19 | −$0.16 | $0.06 |
| Free cash flow per share | −$0.25 | −$0.30 | −$0.06 | −$0.17 | $0.01 | $0.01 | −$0.31 | −$0.24 | −$0.25 | $0.02 |
| Cash per share | $0.49 | $0.62 | $0.13 | $0.21 | $0.21 | $0.11 | $0.14 | $0.17 | $0.16 | $0.34 |
| Book value per share | $1.69 | $1.97 | $1.85 | $2.17 | $2.60 | $2.61 | $2.71 | $3.16 | $3.30 | $4.17 |
| Tangible book value per share | $0.36 | $0.04 | −$0.19 | −$0.07 | $0.39 | −$0.12 | −$0.54 | −$0.43 | −$0.37 | $0.08 |
| Dividends per share | — | — | — | — | — | — | $0.00 | — | $0.00 | $0.00 |
| Capex per share | $0.02 | $0.04 | $0.02 | $0.03 | $0.05 | $0.05 | $0.02 | $0.05 | $0.08 | $0.05 |
| Debt per share | $0.58 | $0.73 | $0.43 | $0.42 | $0.39 | $0.46 | $0.48 | $0.38 | $0.28 | $0.18 |
| Shares outstanding | 751.1M | 694.0M | 751.8M | 719.1M | 648.1M | 640.7M | 595.5M | 566.7M | 559.2M | 502.0M |
| Change in shares outstanding | +8.2% | −7.7% | +4.5% | +11.0% | +1.2% | +7.6% | +5.1% | +1.3% | +11.4% | +0.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −17.1% | −3.9% | −12.8% | −20.2% | −1.8% | 1.9% | −18.5% | −8.4% | −15.5% | −2.4% |
| Return on invested capital (ROIC) | −12.5% | −7.9% | −7.4% | −10.2% | 0.8% | 2.0% | −11.6% | −7.1% | −11.1% | −3.0% |
| Return on assets (ROA) | −10.9% | −2.5% | −9.0% | −14.4% | −1.2% | 1.3% | −13.2% | −6.1% | −11.4% | −1.7% |
| Return on tangible assets | −24.2% | −6.2% | −39.5% | −59.4% | −3.1% | 4.2% | −83.9% | −36.9% | −56.4% | −6.8% |
| Free cash flow margin | −31.4% | −29.2% | −5.2% | −11.9% | 0.3% | 0.4% | −20.5% | −13.8% | −14.3% | 0.7% |
| Income quality (OCF / net income) | — | — | — | — | — | 1.29 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $433.6M | $504.4M | $326.6M | $305.5M | $254.8M | $294.6M | $288.3M | $213.5M | $158.0M | $88.7M |
| Cash & short-term investments | $369.1M | $431.9M | $95.9M | $153.2M | $134.7M | $72.2M | $85.5M | $96.5M | $91.5M | $168.7M |
| Net debt | $64.5M | $72.5M | $230.7M | $152.4M | $120.0M | $222.4M | $202.8M | $117.0M | $66.5M | −$80.0M |
| Debt / equity | 0.34 | 0.37 | 0.24 | 0.20 | 0.15 | 0.18 | 0.18 | 0.12 | 0.09 | 0.04 |
| Debt / assets | 0.22 | 0.23 | 0.16 | 0.14 | 0.11 | 0.12 | 0.12 | 0.09 | 0.06 | 0.03 |
| Net debt / EBITDA | — | 0.54 | — | — | 1.44 | 1.43 | — | — | — | −11.13 |
| Current ratio | 3.97 | 3.43 | 1.55 | 1.85 | 2.49 | 1.39 | 1.30 | 1.24 | 1.12 | 1.84 |
| Quick ratio | 3.52 | 3.13 | 1.22 | 1.50 | 2.23 | 1.04 | 1.09 | 1.07 | 0.96 | 1.66 |
| Interest coverage | -2.0 | -3.2 | -11.6 | -18.8 | 1.0 | 2.6 | -12.7 | -14.4 | -41.9 | -9.9 |
| Working capital | $435.2M | $469.0M | $109.4M | $181.0M | $493.0M | $147.7M | $74.9M | $60.9M | $36.8M | $220.3M |
| Invested capital | $1.33B | $1.44B | $1.62B | $1.71B | $1.81B | $1.89B | $1.82B | $1.91B | $1.91B | $2.01B |
| Tangible asset value | $267.4M | $24.6M | −$144.3M | −$52.7M | $252.6M | −$74.3M | −$319.2M | −$244.7M | −$204.7M | $37.9M |
| Net current asset value | −$82.1M | −$172.7M | −$313.0M | −$211.1M | $108.4M | −$278.3M | −$370.5M | −$342.1M | −$397.5M | −$191.2M |
| Graham number | — | — | — | — | — | $1.67 | — | — | — | — |
| Graham net-net per share | −$0.22 | −$0.38 | −$0.53 | −$0.42 | −$0.52 | −$0.68 | −$0.78 | −$0.74 | −$0.88 | −$0.59 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | $3,000 | — | $0 | $0 |
| Share buybacks (net) | $47.0M | $90.2M | $272,000 | $0 | — | — | $3,000 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 2.0% | 3.5% | 1.9% | 2.4% | 1.8% | 2.3% | 1.4% | 2.8% | 4.8% | 1.9% |
| Capex / operating cash flow | — | — | — | — | 83.9% | 85.3% | — | — | — | 73.5% |
| Capex / depreciation | 0.13 | 0.25 | 0.15 | 0.23 | 0.41 | 0.39 | 0.14 | 0.29 | 0.46 | 0.24 |
| Stock-based compensation / revenue | 1.8% | 1.5% | 1.3% | 1.8% | 0.8% | 0.6% | 1.5% | 2.2% | 2.9% | 3.5% |
| R&D / revenue | 20.4% | 14.8% | 10.4% | 7.4% | 4.3% | 5.2% | 13.1% | 13.7% | 13.1% | 9.3% |
| SG&A / revenue | 36.7% | 42.7% | 34.9% | 37.1% | 26.4% | 24.8% | 38.1% | 36.2% | 53.9% | 40.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 83.6 | 72.2 | 58.9 | 75.3 | 58.4 | 58.5 | 64.7 | 64.3 | 82.5 | 68.5 |
| Days of inventory on hand | 46.7 | 55.6 | 46.8 | 40.9 | 33.5 | 37.9 | 30.5 | 27.7 | 28.4 | 25.9 |
| Days payables outstanding | 33.6 | 53.0 | 45.7 | 38.0 | 28.0 | 33.3 | 35.0 | 36.7 | 37.6 | 37.6 |
| Cash conversion cycle (days) | 96.8 | 74.8 | 60.0 | 78.2 | 63.9 | 63.0 | 60.2 | 55.2 | 73.3 | 56.8 |
| Receivables turnover | 4.36 | 5.05 | 6.19 | 4.85 | 6.25 | 6.24 | 5.64 | 5.67 | 4.43 | 5.33 |
| Payables turnover | 10.86 | 6.89 | 7.98 | 9.61 | 13.05 | 10.95 | 10.42 | 9.94 | 9.71 | 9.71 |
| Inventory turnover | 7.81 | 6.57 | 7.80 | 8.92 | 10.90 | 9.63 | 11.96 | 13.20 | 12.84 | 14.07 |
| Asset turnover | 0.29 | 0.34 | 0.41 | 0.44 | 0.73 | 0.60 | 0.38 | 0.39 | 0.36 | 0.44 |
| Average receivables | $139.1M | $141.1M | $139.4M | $207.1M | $283.9M | $230.0M | $159.8M | $174.5M | $218.3M | $229.2M |
| Average payables | $44.1M | $58.4M | $68.3M | $74.5M | $91.5M | $81.7M | $55.0M | $60.9M | $63.8M | $62.9M |
| Average inventory | $61.3M | $61.2M | $69.9M | $80.3M | $109.4M | $92.9M | $47.9M | $45.8M | $48.3M | $43.5M |
| Intangibles / total assets | 51.8% | 60.9% | 76.2% | 74.5% | 59.7% | 70.6% | 83.8% | 83.1% | 79.1% | 74.2% |
Computed from OPK's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OPK valuation and financial ratios
OPKO Health earned a return on equity of −17.1% and a return on invested capital of −12.5% in fiscal 2025. It ended the year with $433.6 million of debt and $369.1 million in cash and short-term investments, net debt of $64.5 million. It returned $47.0 million to shareholders: $0 in dividends and $47.0 million in share buybacks. The share count rose 49.6% from 502.0M to 751.1M over 9 years.
See the OPK income statement, the OPK chart for price history, or the OPK stock overview for the latest quote and news.
OPK key metrics FAQ
What is OPKO Health's return on equity?
OPKO Health's return on equity (ROE) was −17.1% in fiscal 2025: net income of -$225.7 million on average shareholders' equity of $1.3 billion.
What is OPKO Health's ROIC?
OPKO Health's return on invested capital was −12.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does OPKO Health have?
OPKO Health had total debt of $433.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.34.
Does OPKO Health buy back its shares?
Yes. OPKO Health spent $47.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +8.2% over the year, to 751.1M..
What is OPKO Health's free cash flow yield?
OPKO Health generated -$190.8 million of free cash flow in fiscal 2025, a free cash flow yield of −20.2% on its market value at year-end ($946.4 million).
What is OPKO Health's current ratio?
OPKO Health's current ratio was 3.97 at the end of fiscal 2025: current assets were 3.97 times current liabilities.